• Je něco špatně v tomto záznamu ?

Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells

H. Gbelcová, S. Rimpelová, Z. Knejzlík, J. Šáchová, M. Kolář, H. Strnad, V. Repiská, WC. D'Acunto, T. Ruml, L. Vítek,

. 2017 ; 16 (1) : 250. [pub] 20171220

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033445

BACKGROUND: Statin treatment of hypercholesterolemia is accompanied also with depletion of the mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) necessary for proper function of small GTPases. These include Ras proteins, prevalently mutated in pancreatic cancer. In our study, we evaluated the effect of three key intermediates of the mevalonate pathway on GFP-K-Ras protein localization and the gene expression profile in pancreatic cancer cells after exposure to individual statins. METHODS: These effects were tested on MiaPaCa-2 human pancreatic cancer cells carrying a K-Ras activating mutation (G12C) after exposure to individual statins (20 μM). The effect of statins (atorvastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, rosuvastatin, and pitavastatin) and mevalonate intermediates on GFP-K-Ras protein translocation was analyzed using fluorescence microscopy. The changes in gene expression induced in MiaPaCa-2 cells treated with simvastatin, FPP, GGPP, and their combinations with simvastatin were examined by whole genome DNA microarray analysis. RESULTS: All tested statins efficiently inhibited K-Ras protein trafficking from cytoplasm to the cell membrane of the MiaPaCa-2 cells. The inhibitory effect of statins on GFP-K-Ras protein trafficking was partially prevented by addition of any of the mevalonate pathway's intermediates tested. Expressions of genes involved in metabolic and signaling pathways modulated by simvastatin treatment was normalized by the concurrent addition of FPP or GGPP. K-Ras protein trafficking within the pancreatic cancer cells is effectively inhibited by the majority of statins; the inhibition is eliminated by isoprenoid intermediates of the mevalonate pathway. CONCLUSIONS: Our data indicate that the anticancer effects of statins observed in numerous studies to a large extent are mediated through isoprenoid intermediates of the mevalonate pathway, as they influence expression of genes involved in multiple intracellular pathways.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033445
003      
CZ-PrNML
005      
20181015124136.0
007      
ta
008      
181008s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12944-017-0641-0 $2 doi
035    __
$a (PubMed)29262834
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gbelcová, Helena $u Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia. Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic.
245    10
$a Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells / $c H. Gbelcová, S. Rimpelová, Z. Knejzlík, J. Šáchová, M. Kolář, H. Strnad, V. Repiská, WC. D'Acunto, T. Ruml, L. Vítek,
520    9_
$a BACKGROUND: Statin treatment of hypercholesterolemia is accompanied also with depletion of the mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) necessary for proper function of small GTPases. These include Ras proteins, prevalently mutated in pancreatic cancer. In our study, we evaluated the effect of three key intermediates of the mevalonate pathway on GFP-K-Ras protein localization and the gene expression profile in pancreatic cancer cells after exposure to individual statins. METHODS: These effects were tested on MiaPaCa-2 human pancreatic cancer cells carrying a K-Ras activating mutation (G12C) after exposure to individual statins (20 μM). The effect of statins (atorvastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, rosuvastatin, and pitavastatin) and mevalonate intermediates on GFP-K-Ras protein translocation was analyzed using fluorescence microscopy. The changes in gene expression induced in MiaPaCa-2 cells treated with simvastatin, FPP, GGPP, and their combinations with simvastatin were examined by whole genome DNA microarray analysis. RESULTS: All tested statins efficiently inhibited K-Ras protein trafficking from cytoplasm to the cell membrane of the MiaPaCa-2 cells. The inhibitory effect of statins on GFP-K-Ras protein trafficking was partially prevented by addition of any of the mevalonate pathway's intermediates tested. Expressions of genes involved in metabolic and signaling pathways modulated by simvastatin treatment was normalized by the concurrent addition of FPP or GGPP. K-Ras protein trafficking within the pancreatic cancer cells is effectively inhibited by the majority of statins; the inhibition is eliminated by isoprenoid intermediates of the mevalonate pathway. CONCLUSIONS: Our data indicate that the anticancer effects of statins observed in numerous studies to a large extent are mediated through isoprenoid intermediates of the mevalonate pathway, as they influence expression of genes involved in multiple intracellular pathways.
650    _2
$a anticholesteremika $x farmakologie $7 D000924
650    _2
$a atorvastatin $x farmakologie $7 D000069059
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a kyseliny mastné mononenasycené $x farmakologie $7 D005229
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a regulace genové exprese $7 D005786
650    _2
$a zelené fluorescenční proteiny $x genetika $x metabolismus $7 D049452
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x farmakologie $7 D007211
650    _2
$a beta-buňky $x účinky léků $x metabolismus $x patologie $7 D050417
650    _2
$a lovastatin $x farmakologie $7 D008148
650    _2
$a kyselina mevalonová $x analogy a deriváty $x farmakologie $7 D008798
650    _2
$a mikročipová analýza $7 D046228
650    _2
$a mutace $7 D009154
650    _2
$a polyisoprenylfosfáty $x farmakologie $7 D011106
650    _2
$a prenylace proteinů $7 D017368
650    _2
$a transport proteinů $x účinky léků $7 D021381
650    _2
$a protoonkogenní proteiny p21(ras) $x genetika $x metabolismus $7 D016283
650    _2
$a rekombinantní fúzní proteiny $x genetika $x metabolismus $7 D011993
650    _2
$a seskviterpeny $x farmakologie $7 D012717
650    _2
$a signální transdukce $7 D015398
650    _2
$a simvastatin $x farmakologie $7 D019821
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rimpelová, Silvie $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic.
700    1_
$a Knejzlík, Zdeněk $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic.
700    1_
$a Šáchová, Jana $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Kolář, Michal $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Strnad, Hynek $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Repiská, Vanda $u Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a D'Acunto, Walter Cosimo $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic.
700    1_
$a Ruml, Tomáš $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic. tomas.ruml@vscht.cz.
700    1_
$a Vítek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, and 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. vitek@cesnet.cz.
773    0_
$w MED00008241 $t Lipids in health and disease $x 1476-511X $g Roč. 16, č. 1 (2017), s. 250
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29262834 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181015124632 $b ABA008
999    __
$a ok $b bmc $g 1340159 $s 1030439
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 16 $c 1 $d 250 $e 20171220 $i 1476-511X $m Lipids in health and disease $n Lipids Health Dis $x MED00008241
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...